Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Saturn Pharmaceuticals CEO resigns after indictment

Executive Summary

Former Bristol-Myers Squibb exec Richard Lane resigns from CEO post at Saturn Pharmaceuticals following his June 15 indictment. As the former head of Bristol's wordwide medicines group, Lane, along with former Bristol CFO Fred Schiff, was indicted on charges of securities fraud and conspiracy to commit securities fraud in connection with a Newark, N.J. U.S. Attorney's Office investigation into Bristol's past "channel stuffing" and accounting practices (1"The Pink Sheet" June 20, 2005, p. 18). Indevus, which copromotes Sanctura with Saturn, announced John Spitznagel will be Lane's successor at Saturn. Spitznagel formerly was CEO of ESP Pharma; previously he held exec roles at large pharma companies including senior VP-marketing & sales at Wyeth...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS046007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel